The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 16, 2014

Filed:

Aug. 18, 2010
Applicants:

Markus Follmann, Wülfrath, DE;

Volkmar Wehner, Frankurt am Main, DE;

Jean-michel Altenburger, Paris, FR;

Gilbert Lassalle, Paris, FR;

Jean-pascal Herault, Paris, FR;

Inventors:

Markus Follmann, Wülfrath, DE;

Volkmar Wehner, Frankurt am Main, DE;

Jean-Michel Altenburger, Paris, FR;

Gilbert Lassalle, Paris, FR;

Jean-Pascal Herault, Paris, FR;

Assignee:

Sanofi, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/14 (2006.01); A61K 31/55 (2006.01); A61P 9/10 (2006.01); A61P 7/02 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); C07D 413/04 (2006.01);
U.S. Cl.
CPC ...
C07D 413/14 (2013.01); C07D 413/04 (2013.01);
Abstract

The present invention relates to compounds of the formula I, wherein R1; R2; R3; R4; R5, R16, X and M have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa and thrombin and can in general be applied in conditions in which an undesired activity of factor Xa and/or thrombin are present or for the cure or prevention of which an inhibition of factor Xa and thrombin are intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.


Find Patent Forward Citations

Loading…